Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Spillmann

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
MMW Fortschritte Der Medizin|March 5, 2019
[Suspected acute decompensated heart failure]Gunther Schmidt, Frank Spillmann, Carsten Tschöpe
European Journal of Heart Failure|February 12, 2025
Empagliflozin's anti-inflammatory spectrum in type 2 diabetes mellitus: Piecing together the puzzleSophie Van Linthout, Frank Spillmann, Subodh Verma
Endocrine, Metabolic & Immune Disorders Drug Targets|January 13, 2012
Cardiac effects of HDL and its components on diabetic cardiomyopathyFrank Spillmann, Sophie Van Linthout, Carsten Tschöpe
Current Pharmaceutical Design|March 4, 2010
High-density lipoprotein-raising strategies: update 2010Frank Spillmann, Heinz-Peter Schultheiss, Carsten Tschöpe, et al.
Current Opinion in Nephrology and Hypertension|December 13, 2005
Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathyFrank Spillmann, Sophie Van Linthout, Heinz-Peter Schultheiss, et al.
Current Pharmaceutical Design|March 4, 2010
High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disordersSophie Van Linthout, Frank Spillmann, Heinz-Peter Schultheiss, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 20, 2015
High-density lipoproteins reduce endothelial-to-mesenchymal transitionFrank Spillmann, Kapka Miteva, Burkert Pieske, et al.
BMC Cardiovascular Disorders|September 23, 2017
Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?Michael Schwarzer, Michel Noutsias, Frank Spillmann, et al.
Biological Chemistry|July 17, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat modelMatthias Koch, Klaus Bonaventura, Frank Spillmann, et al.
Atherosclerosis|January 10, 2014
LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effectsFrank Spillmann, Sophie Van Linthout, Kapka Miteva, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
MMW Fortschritte Der Medizin|March 5, 2019
[Suspected acute decompensated heart failure]Gunther Schmidt, Frank Spillmann, Carsten Tschöpe
European Journal of Heart Failure|February 12, 2025
Empagliflozin's anti-inflammatory spectrum in type 2 diabetes mellitus: Piecing together the puzzleSophie Van Linthout, Frank Spillmann, Subodh Verma
Endocrine, Metabolic & Immune Disorders Drug Targets|January 13, 2012
Cardiac effects of HDL and its components on diabetic cardiomyopathyFrank Spillmann, Sophie Van Linthout, Carsten Tschöpe
Current Pharmaceutical Design|March 4, 2010
High-density lipoprotein-raising strategies: update 2010Frank Spillmann, Heinz-Peter Schultheiss, Carsten Tschöpe, et al.
Current Opinion in Nephrology and Hypertension|December 13, 2005
Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathyFrank Spillmann, Sophie Van Linthout, Heinz-Peter Schultheiss, et al.
Current Pharmaceutical Design|March 4, 2010
High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disordersSophie Van Linthout, Frank Spillmann, Heinz-Peter Schultheiss, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 20, 2015
High-density lipoproteins reduce endothelial-to-mesenchymal transitionFrank Spillmann, Kapka Miteva, Burkert Pieske, et al.
BMC Cardiovascular Disorders|September 23, 2017
Complexity of pathomechanisms leading to diastolic heart failure in diabetes mellitus - potential field for therapeutic interventions?Michael Schwarzer, Michel Noutsias, Frank Spillmann, et al.
Biological Chemistry|July 17, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat modelMatthias Koch, Klaus Bonaventura, Frank Spillmann, et al.
Atherosclerosis|January 10, 2014
LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effectsFrank Spillmann, Sophie Van Linthout, Kapka Miteva, et al.
Pageof 6